EGFR and non-small cell lung carcinoma: Building on the successful results of first-generation EGFR-TKIs combined with antiangiogenic agents, a few phase II trials have evaluated the efficacy of osimertinib plus antiangiogenic agents for previously untreated patients with advanced NSCLC harboring EGFR mutations [82–84].